TEST:

NeXT Dx™ Test

"Personalis, Inc...today announced it has received a final Medicare coverage determination for its NeXT Dx ultra-comprehensive tumor genomic profiling assay, providing access for the nation’s 66 million Medicare and Medicare Advantage beneficiaries....NeXT Dx analyzes a tumor’s entire exome (DNA) and transcriptome (RNA) to uncover deeper insights into therapy selection, including RNA-based fusions and advanced biomarkers that smaller panels might miss, such as tumor mutational burden (TMB) and microsatellite instability (MSI). In addition, NeXT Dx utilizes paired tumor and non-tumor samples to report more accurate results."

NeXT Dx demonstrated analytic sensitivities as follows: SNVs (99.4%), indels (98.2%), CNAs (98.0%), and fusions (95.8%). The overall analytic specificity was >99.0%.

Investor Presentation

Q2 2022 Personalis Inc Earnings Call

"Personalis, Inc...announced the issuance of two key US Patents related to its high-performance, exome-wide liquid biopsy platform, NeXT Liquid Biopsy...The first patent, US Patent No. 11,142,802, entitled 'Methods for Using Mosaicism in Nucleic Acids Sampled Distal to Their Origin', issued on October 12, 2021...The second patent, US Patent No. 11,155,867, entitled 'Methods and Systems for Genetic Analysis', issued on October 26, 2021."